We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
The transaction consideration includes an initial payment of $200m upon closing, and contingent milestones-based and non-contingent consideration of up to $120m, and is expected to close in the first quarter of 2023
To be available from January 2023, SymbioLife Satylia is a new dietary
AstraZeneca will develop and market an oral therapy for the treatment of
The clinical-stage company took an immunoproteomics approach to extract and identify naturally
The Taiwan Food and Drug Administration has granted accelerated approval designation (AAD),
